Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Regencell Bioscience Holdings Ltd RGC

Regencell Bioscience Holdings Ltd is a bioscience company that focuses on research, development and commercialization of traditional Chinese medicine (TCM) for the treatment of neurocognitive disorders and degeneration, specifically attention deficit and hyperactivity disorder (ADHD) and autism spectrum disorder (ASD). The Company launches three liquid based standardized TCM formulae candidates for mild, moderate and severe ADHD and ASD patients.


NDAQ:RGC - Post by User

Post by sungrin1309on Nov 25, 2022 8:31am
93 Views
Post# 35127669

$RGC Potential Bagger healthcare Company - HOT STOCK -

$RGC Potential Bagger healthcare Company - HOT STOCK -Regencel Bioscience Holding is a R&D and Commercialize Healthcare company that focusses on treating ADHD, ASD and COVID-19 using Traditional Chinese Medicine (”TCM”) approach.

The company’s stock has seen rough days of being shorted by both short sellers and traders alike and the Company CEO has not taken this event without a stand. Mr Au, the CEO of Regencell has voiced out “Short and distort schemes used on our stock are negatively affecting our company. These schemes hurt our investors and patients, especially children and their families who are looking for a natural approach to treat attention hyperactivity disorder (“ADHD”), autism spectrum disorder (“ASD”) and COVID-19, and have the potential to disrupt our mission to help our patients.”

[https://www.morningstar.com/news/business-wire/20220516005531/regencell-bioscience-holdings-limited-announces-over-5-million-ordinary-share-purchases-by-ceo]

Mr Au took further response by buying back over 5 million ordinary shares to defend the company against these short sellers and has also announced that he will not be drawing salary nor bonus (<1$) until the company reaches $1 Billion USD.

Further stance were taken by the company’s directors and employees where stock options which were previously granted upon company IPO will be subjected to a lock-up of 6 months vesting period. The shares will be locked up until January 16, 2023.
<< Previous
Bullboard Posts
Next >>